Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

2
Bed Bath But Not Beyond Hope

15h seekingalpha
BBBY has lost 70% of its peak value. Profits are down mostly due to price competition. Store comparable sales have been falling mid-single digits, offset by growth in digital.
BBBY

17
Amazon Prime Day 2018 Will Be Huge

17h seekingalpha
Its that time of year again, with the fourth Prime Day scheduled to kick off at 3 pm E.T on Monday, July 16th. Wall Street (i.e. the sell side) has been fairly quiet about Prime Day this year vs. last year. Perhaps their attention are fixated on trade tensions between China and the US, and on Amazon's recent foray into healthcare. However, they should be thinking more about Prime Day 2018, which I think is set to exceed all expectations.
WFM TGT KSS M BBBY WMT

3
Bed Bath & Beyond Might Not Be Undervalued

2018-07-13 seekingalpha
BBBY is selling at a slight discount to book value and at a low P/E multiple.
JCP BBBY

2
BBBY / Bed Bath & Beyond Inc. / BlackRock Inc. - null (Passive Investment)

2018-07-10 sec.gov
us0758961009_070518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 6) BED BATH AND BEYOND INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 075896100 -------------------------------------------------------- (CUSIP Number) June 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cove
BBBY

2
BBBY / Bed Bath & Beyond Inc. / BlackRock Inc. - null (Passive Investment)

2018-07-10 sec.gov
us0758961009_070518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 6) BED BATH AND BEYOND INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 075896100 -------------------------------------------------------- (CUSIP Number) June 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cove
BBBY

2
Wayfair Should Pull An AOL/Timer Warner And Acquire Bed Bath & Beyond

2018-07-05 seekingalpha
The Uber Bear Narrative in Brick and Mortar retail is now dead. The story going forward is Omnichannel, and that doesn't bode well for Wayfair.
W BBBY

2
Bed Bath & Beyond - Expecting Short-Term Relief, But The Main Fundamental Issues Remain

2018-07-05 seekingalpha
Bed Bath & Beyond (BBBY) has recently posted another disappointing quarter. Net sales were just slightly up (+0.40%), comps were down a bit (-0.6%) and below the top-line, the old problems are still as evident as before. The company’s increasing promotional activity and excessive reliance on coupons to drive store traffic and sales have been pressuring margins for years. They are the factors that made BBBY a value trap.
BBBY

10
Five Below - Strong Growth But Major Headwinds On The Horizon

2018-07-05 seekingalpha
While quarterly results and guidance were solid, the stock overreacted, and valuation is now extremely stretched.
XKE TGT DKS KSS TRI BKS FIVE WMT BBBY

17
Margin Pressures Make It Tough To Like Bed Bath & Beyond Stock

2018-06-28 seekingalpha
BBBY's business could stabilize over the next several years, but the stock is already priced for that.
BBBY

28
Bed Bath & Beyond (BBBY) Down Despite Q1 Earnings & Sales Beat

2018-06-28 zacks
Bed Bath & Beyond Inc. (BBBY - Free Report) delivered better-than-expected results in first-quarter fiscal 2018, wherein the top and bottom line outpaced the Zacks Consensus Estimate. In fact, this marked the company’s third straight quarter of earnings and sales beat. However, decline in comparable sales (comps) along with contraction in both gross and operating margin has hurt the investor sentiment.
BGFV TSCO FIVE BBBY

17
Options Traders Expect Huge Moves in Bed Bath & Beyond (BBBY) Stock

2018-06-28 zacks
Investors in Bed Bath & Beyond Inc. (BBBY - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 29, 2018 $18 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
BBBY

18
Why Bed Bath & Beyond Keeps Disappointing on Earnings

2018-06-28 247wallst
Bed Bath & Beyond Inc. (NASDAQ: BBBY) is a company that just cannot seem to have a good earnings report these days. Even when the retailer of home goods beats on earnings, there usually seems to be some disappointment in same-store sales or other revenue metrics.
TRI BBBY

21
Bed Bath & Beyond Inc. (BBBY) CEO Steven Temares on Q1 2018 Results - Earnings Call Transcript

2018-06-28 seekingalpha
Bed Bath & Beyond Inc. (NASDAQ:BBBY) Q1 2018 Earnings Conference Call June 27, 2018 5:00 PM ET
DB BBBY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

4h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

5h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to BBBY / Bed Bath & Beyond Inc. on message board site Silicon Investor.

Bed, Bath, and Beyond (BBBY) ABB and ABB ADRu0027s (ABBBY)
CUSIP: 075896100